Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design of a FAIR digital data health infrastructure in Africa for COVID-19 reporting and research.
van Reisen M, Oladipo F, Stokmans M, Mpezamihgo M, Folorunso S, Schultes E, Basajja M, Aktau A, Amare SY, Taye GT, Purnama Jati PH, Chindoza K, Wirtz M, Ghardallou M, van Stam G, Ayele W, Nalugala R, Abdullahi I, Osigwe O, Graybeal J, Medhanyie AA, Kawu AA, Liu F, Wolstencroft K, Flikkenschild E, Lin Y, Stocker J, Musen MA. van Reisen M, et al. Adv Genet (Hoboken). 2021 Jun;2(2):e10050. doi: 10.1002/ggn2.10050. Epub 2021 Jun 11. Adv Genet (Hoboken). 2021. PMID: 34514430 Free PMC article.
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP. Ataga KI, et al. Among authors: stocker jw. N Engl J Med. 2017 Feb 2;376(5):429-439. doi: 10.1056/NEJMoa1611770. Epub 2016 Dec 3. N Engl J Med. 2017. PMID: 27959701 Free PMC article. Clinical Trial.
Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043).
Ataga KI, Reid M, Ballas SK, Yasin Z, Bigelow C, James LS, Smith WR, Galacteros F, Kutlar A, Hull JH, Stocker JW; ICA-17043-10 Study Investigators. Ataga KI, et al. Among authors: stocker jw. Br J Haematol. 2011 Apr;153(1):92-104. doi: 10.1111/j.1365-2141.2010.08520.x. Epub 2011 Feb 17. Br J Haematol. 2011. PMID: 21323872 Free article. Clinical Trial.
35 results